Eli Lilly revealed major advancements in its alopecia and atopic dermatitis studies, likely driving its 3.77% stock rise. The ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The company has experienced a mixed financial performance, with a miss in Q4 ...

Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available for $499 per month using its new Zepbound Self Pay Journey Program. 1 The ...

Tablet shows same established efficacy and safety as the Evrysdi oral solution. HealthDay News — The U.S. Food and Drug Administration has approved a new drug application for a tablet version of ...

GlobalData is the parent company of Clinical Trials Arena. In terms of competition, there are currently only two other IL-23 inhibitors approved in the US besides Tremfya – Eli Lilly’s Omvoh ...

US healthcare giant Johnson & Johnson (NYSE: JNJ) has announced data from the Phase III ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely ...

showing that most patients with moderately to severely active Crohn’s disease achieved long-term clinical and endoscopic improvements after two years of continuous treatment with Omvoh.

It is not known whether Omvoh (mirikizumab-mrkz) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy may ...

Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease Omvoh (mirikizumab-mrkz) Humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of ...